Immortalized Parkinson's disease lymphocytes have enhanced mitochondrial respiratory activity

Sarah J. Annesley, Sui T. Lay, Shawn W. De Piazza, Oana Sanislav, Eleanor Hammersley, Claire Y. Allan, Lisa M. Francione, Minh Q. Bui, Zhi Ping Chen, Kevin R W Ngoei, Flora Tassone, Bruce E. Kemp, Elsdon Storey, Andrew Evans, Danuta Z. Loesch, Paul R. Fisher

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In combination with studies of post-mortem Parkinson's disease (PD) brains, pharmacological and genetic models of PD have suggested that two fundamental interacting cellular processes are impaired-proteostasis and mitochondrial respiration. We have re-examined the role of mitochondrial dysfunction in lymphoblasts isolated from individuals with idiopathic PD and an age-matched control group. As previously reported forvarious PD cell types, the production of reactive oxygen species (ROS) by PD lymphoblasts was significantly elevated. However, this was not due to an impairment of mitochondrial respiration, as is often assumed. Instead, basal mitochondrial respiration and ATP synthesis are dramatically elevated in PD lymphoblasts. The mitochondrial mass, genome copy number and membrane potential were unaltered, but the expression of indicative respiratory complex proteins was also elevated. This explains the increased oxygen consumption rates by each of the respiratory complexes in experimentally uncoupled mitochondria of iPD cells. However, it was not attributable to increased activity of the stress- and energy-sensing protein kinase AMPK, a regulator of mitochondrial biogenesis and activity. The respiratory differences between iPD and control cells were sufficiently dramatic as to provide a potentially sensitive and reliable biomarker of the disease state, unaffected by disease duration (time since diagnosis) or clinical severity. Lymphoblasts from control and PD individuals thus occupy two distinct, quasi-stable steady states; a 'normal' and a 'hyperactive' state characterized by two different metabolic rates. The apparent stability of the 'hyperactive' state in patient-derived lymphoblasts in the face of patient ageing, ongoing disease and mounting disease severity suggests an early, permanent switch to an alternative metabolic steady state. With its associated, elevated ROS production, the 'hyperactive' state might not cause pathology to cells that are rapidly turned over, but brain cells might accumulate long-term damage leading ultimately to neurodegeneration and the loss of mitochondrial function observed post-mortem. Whether the 'hyperactive' state in lymphoblasts is a biomarker specifically of PD or more generally of neurodegenerative disease remains to be determined.

Original languageEnglish (US)
Pages (from-to)1295-1305
Number of pages11
JournalDMM Disease Models and Mechanisms
Volume9
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

Lymphocytes
Parkinson Disease
Respiration
Reactive Oxygen Species
Biomarkers
AMP-Activated Protein Kinases
Mitochondrial Genome
Genetic Models
Brain
Organelle Biogenesis
Respiratory Rate
Oxygen Consumption
Neurodegenerative Diseases
Membrane Potentials
Neurodegenerative diseases
Protein Kinases
Mitochondria
Research Design
Adenosine Triphosphate
Pathology

Keywords

  • AMPK
  • ATP
  • Complex I
  • Lymphoblast
  • Lymphocyte
  • Mitochondria
  • Oxidative stress
  • OXPHOS
  • Parkinson's disease
  • Respiration
  • ROS

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Medicine (miscellaneous)
  • Immunology and Microbiology (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Annesley, S. J., Lay, S. T., De Piazza, S. W., Sanislav, O., Hammersley, E., Allan, C. Y., ... Fisher, P. R. (2016). Immortalized Parkinson's disease lymphocytes have enhanced mitochondrial respiratory activity. DMM Disease Models and Mechanisms, 9(11), 1295-1305. https://doi.org/10.1242/dmm.025684

Immortalized Parkinson's disease lymphocytes have enhanced mitochondrial respiratory activity. / Annesley, Sarah J.; Lay, Sui T.; De Piazza, Shawn W.; Sanislav, Oana; Hammersley, Eleanor; Allan, Claire Y.; Francione, Lisa M.; Bui, Minh Q.; Chen, Zhi Ping; Ngoei, Kevin R W; Tassone, Flora; Kemp, Bruce E.; Storey, Elsdon; Evans, Andrew; Loesch, Danuta Z.; Fisher, Paul R.

In: DMM Disease Models and Mechanisms, Vol. 9, No. 11, 01.11.2016, p. 1295-1305.

Research output: Contribution to journalArticle

Annesley, SJ, Lay, ST, De Piazza, SW, Sanislav, O, Hammersley, E, Allan, CY, Francione, LM, Bui, MQ, Chen, ZP, Ngoei, KRW, Tassone, F, Kemp, BE, Storey, E, Evans, A, Loesch, DZ & Fisher, PR 2016, 'Immortalized Parkinson's disease lymphocytes have enhanced mitochondrial respiratory activity', DMM Disease Models and Mechanisms, vol. 9, no. 11, pp. 1295-1305. https://doi.org/10.1242/dmm.025684
Annesley SJ, Lay ST, De Piazza SW, Sanislav O, Hammersley E, Allan CY et al. Immortalized Parkinson's disease lymphocytes have enhanced mitochondrial respiratory activity. DMM Disease Models and Mechanisms. 2016 Nov 1;9(11):1295-1305. https://doi.org/10.1242/dmm.025684
Annesley, Sarah J. ; Lay, Sui T. ; De Piazza, Shawn W. ; Sanislav, Oana ; Hammersley, Eleanor ; Allan, Claire Y. ; Francione, Lisa M. ; Bui, Minh Q. ; Chen, Zhi Ping ; Ngoei, Kevin R W ; Tassone, Flora ; Kemp, Bruce E. ; Storey, Elsdon ; Evans, Andrew ; Loesch, Danuta Z. ; Fisher, Paul R. / Immortalized Parkinson's disease lymphocytes have enhanced mitochondrial respiratory activity. In: DMM Disease Models and Mechanisms. 2016 ; Vol. 9, No. 11. pp. 1295-1305.
@article{ed9d8762f4a3421e9233b347c2e90271,
title = "Immortalized Parkinson's disease lymphocytes have enhanced mitochondrial respiratory activity",
abstract = "In combination with studies of post-mortem Parkinson's disease (PD) brains, pharmacological and genetic models of PD have suggested that two fundamental interacting cellular processes are impaired-proteostasis and mitochondrial respiration. We have re-examined the role of mitochondrial dysfunction in lymphoblasts isolated from individuals with idiopathic PD and an age-matched control group. As previously reported forvarious PD cell types, the production of reactive oxygen species (ROS) by PD lymphoblasts was significantly elevated. However, this was not due to an impairment of mitochondrial respiration, as is often assumed. Instead, basal mitochondrial respiration and ATP synthesis are dramatically elevated in PD lymphoblasts. The mitochondrial mass, genome copy number and membrane potential were unaltered, but the expression of indicative respiratory complex proteins was also elevated. This explains the increased oxygen consumption rates by each of the respiratory complexes in experimentally uncoupled mitochondria of iPD cells. However, it was not attributable to increased activity of the stress- and energy-sensing protein kinase AMPK, a regulator of mitochondrial biogenesis and activity. The respiratory differences between iPD and control cells were sufficiently dramatic as to provide a potentially sensitive and reliable biomarker of the disease state, unaffected by disease duration (time since diagnosis) or clinical severity. Lymphoblasts from control and PD individuals thus occupy two distinct, quasi-stable steady states; a 'normal' and a 'hyperactive' state characterized by two different metabolic rates. The apparent stability of the 'hyperactive' state in patient-derived lymphoblasts in the face of patient ageing, ongoing disease and mounting disease severity suggests an early, permanent switch to an alternative metabolic steady state. With its associated, elevated ROS production, the 'hyperactive' state might not cause pathology to cells that are rapidly turned over, but brain cells might accumulate long-term damage leading ultimately to neurodegeneration and the loss of mitochondrial function observed post-mortem. Whether the 'hyperactive' state in lymphoblasts is a biomarker specifically of PD or more generally of neurodegenerative disease remains to be determined.",
keywords = "AMPK, ATP, Complex I, Lymphoblast, Lymphocyte, Mitochondria, Oxidative stress, OXPHOS, Parkinson's disease, Respiration, ROS",
author = "Annesley, {Sarah J.} and Lay, {Sui T.} and {De Piazza}, {Shawn W.} and Oana Sanislav and Eleanor Hammersley and Allan, {Claire Y.} and Francione, {Lisa M.} and Bui, {Minh Q.} and Chen, {Zhi Ping} and Ngoei, {Kevin R W} and Flora Tassone and Kemp, {Bruce E.} and Elsdon Storey and Andrew Evans and Loesch, {Danuta Z.} and Fisher, {Paul R.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1242/dmm.025684",
language = "English (US)",
volume = "9",
pages = "1295--1305",
journal = "DMM Disease Models and Mechanisms",
issn = "1754-8403",
publisher = "Company of Biologists Ltd",
number = "11",

}

TY - JOUR

T1 - Immortalized Parkinson's disease lymphocytes have enhanced mitochondrial respiratory activity

AU - Annesley, Sarah J.

AU - Lay, Sui T.

AU - De Piazza, Shawn W.

AU - Sanislav, Oana

AU - Hammersley, Eleanor

AU - Allan, Claire Y.

AU - Francione, Lisa M.

AU - Bui, Minh Q.

AU - Chen, Zhi Ping

AU - Ngoei, Kevin R W

AU - Tassone, Flora

AU - Kemp, Bruce E.

AU - Storey, Elsdon

AU - Evans, Andrew

AU - Loesch, Danuta Z.

AU - Fisher, Paul R.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - In combination with studies of post-mortem Parkinson's disease (PD) brains, pharmacological and genetic models of PD have suggested that two fundamental interacting cellular processes are impaired-proteostasis and mitochondrial respiration. We have re-examined the role of mitochondrial dysfunction in lymphoblasts isolated from individuals with idiopathic PD and an age-matched control group. As previously reported forvarious PD cell types, the production of reactive oxygen species (ROS) by PD lymphoblasts was significantly elevated. However, this was not due to an impairment of mitochondrial respiration, as is often assumed. Instead, basal mitochondrial respiration and ATP synthesis are dramatically elevated in PD lymphoblasts. The mitochondrial mass, genome copy number and membrane potential were unaltered, but the expression of indicative respiratory complex proteins was also elevated. This explains the increased oxygen consumption rates by each of the respiratory complexes in experimentally uncoupled mitochondria of iPD cells. However, it was not attributable to increased activity of the stress- and energy-sensing protein kinase AMPK, a regulator of mitochondrial biogenesis and activity. The respiratory differences between iPD and control cells were sufficiently dramatic as to provide a potentially sensitive and reliable biomarker of the disease state, unaffected by disease duration (time since diagnosis) or clinical severity. Lymphoblasts from control and PD individuals thus occupy two distinct, quasi-stable steady states; a 'normal' and a 'hyperactive' state characterized by two different metabolic rates. The apparent stability of the 'hyperactive' state in patient-derived lymphoblasts in the face of patient ageing, ongoing disease and mounting disease severity suggests an early, permanent switch to an alternative metabolic steady state. With its associated, elevated ROS production, the 'hyperactive' state might not cause pathology to cells that are rapidly turned over, but brain cells might accumulate long-term damage leading ultimately to neurodegeneration and the loss of mitochondrial function observed post-mortem. Whether the 'hyperactive' state in lymphoblasts is a biomarker specifically of PD or more generally of neurodegenerative disease remains to be determined.

AB - In combination with studies of post-mortem Parkinson's disease (PD) brains, pharmacological and genetic models of PD have suggested that two fundamental interacting cellular processes are impaired-proteostasis and mitochondrial respiration. We have re-examined the role of mitochondrial dysfunction in lymphoblasts isolated from individuals with idiopathic PD and an age-matched control group. As previously reported forvarious PD cell types, the production of reactive oxygen species (ROS) by PD lymphoblasts was significantly elevated. However, this was not due to an impairment of mitochondrial respiration, as is often assumed. Instead, basal mitochondrial respiration and ATP synthesis are dramatically elevated in PD lymphoblasts. The mitochondrial mass, genome copy number and membrane potential were unaltered, but the expression of indicative respiratory complex proteins was also elevated. This explains the increased oxygen consumption rates by each of the respiratory complexes in experimentally uncoupled mitochondria of iPD cells. However, it was not attributable to increased activity of the stress- and energy-sensing protein kinase AMPK, a regulator of mitochondrial biogenesis and activity. The respiratory differences between iPD and control cells were sufficiently dramatic as to provide a potentially sensitive and reliable biomarker of the disease state, unaffected by disease duration (time since diagnosis) or clinical severity. Lymphoblasts from control and PD individuals thus occupy two distinct, quasi-stable steady states; a 'normal' and a 'hyperactive' state characterized by two different metabolic rates. The apparent stability of the 'hyperactive' state in patient-derived lymphoblasts in the face of patient ageing, ongoing disease and mounting disease severity suggests an early, permanent switch to an alternative metabolic steady state. With its associated, elevated ROS production, the 'hyperactive' state might not cause pathology to cells that are rapidly turned over, but brain cells might accumulate long-term damage leading ultimately to neurodegeneration and the loss of mitochondrial function observed post-mortem. Whether the 'hyperactive' state in lymphoblasts is a biomarker specifically of PD or more generally of neurodegenerative disease remains to be determined.

KW - AMPK

KW - ATP

KW - Complex I

KW - Lymphoblast

KW - Lymphocyte

KW - Mitochondria

KW - Oxidative stress

KW - OXPHOS

KW - Parkinson's disease

KW - Respiration

KW - ROS

UR - http://www.scopus.com/inward/record.url?scp=84994689618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994689618&partnerID=8YFLogxK

U2 - 10.1242/dmm.025684

DO - 10.1242/dmm.025684

M3 - Article

C2 - 27638668

AN - SCOPUS:84994689618

VL - 9

SP - 1295

EP - 1305

JO - DMM Disease Models and Mechanisms

JF - DMM Disease Models and Mechanisms

SN - 1754-8403

IS - 11

ER -